CHANGING THE PARADIGM
OF MEDICINE
Developing a novel class of complete microbiota ecosystem products and
microbiome therapies to address unmet challenges in human diseases.
Our preclinical stage programs and related information are disclosed below:
| Program | Indication | Product Type(s) | Discovery | Preclinical | Clinical |
|---|---|---|---|---|---|
| MVT-201 | Infectious Diseases | Complete Microbiota HPM® | |||
| MVT-601 | Skin disorder | Bacterial consortia & HPM® | |||
| MVT-2401 | Oncology | Bacterial consortia & HPM® | |||
| MVT-701 | Healthy ageing | Bacterial consortia | |||
| MVT-1001 | Sports performance | Bacterial consortia |
Program: MVT-201
Indication:Infectious Diseases
Product Type(s): Complete Microbiota HPM®
Preclinical Fase
Program: MVT-601
Indication: Skin disorder
Product Type(s): Bacterial consortia & HPM®
Preclinical Fase
Program: MVT-2401
Indication:Oncology
Product Type(s): Bacterial consortia & HPM®
Discovery fase
Program: MVT-701
Indication: Healthy ageing
Product type(s): Bacterial consortia
Preclinical fase
Program: MVT-1001
Indication:Sports performance
Product type(s): Bacterial consortia
Preclinical fase
Over the last years we have built our platform powered by innovation leading to tangible products and services already marketed.
We are currently focused on developing novel biotherapeutics based on complete microbiota ecosystem products that are at preclinical stage for various medical applications. Additionally, we have a large and diverse bacterial strain collection for the development of novel LBPs and probiotics to cover the patients’ needs.